NCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT01189370 2017-06-01
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT00657254 2014-12-23
Extension Program for Bay 43-9006
Bayer
Phase 2 Completed
NCT00079612 2014-12-19
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Bayer
Phase 2 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00117637 2014-10-31
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00044512 2014-04-16
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00101400 2013-12-13
BAY43-9006 - Phase II in Advanced Breast Cancer
Bayer
Phase 2 Completed
NCT00101413 2013-10-30
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Bayer
Phase 2 Completed
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT00498836 2013-09-12
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Clavis Pharma
Phase 2 Completed
NCT00098254 2012-05-02
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00430235 2010-08-05
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
British Columbia Cancer Agency
Phase 2 Completed